

**Connie B. Newman, MD, FACP, FAHA, FAMWA**  
**Adjunct Professor of Medicine, NYU School of Medicine**  
**Connie.newman@nyulangone.org**

Dr. Connie Newman is an endocrinologist and Adjunct Professor of Medicine at New York University School of Medicine, where she has been a full time (tenured) or part time member of the faculty since 1984. She is an Academic Visitor at University of Oxford, UK. She is certified by the American Board of Internal Medicine (1981) and the Subspecialty Board of Endocrinology and Metabolism (1983). She graduated from Weill Cornell Medical College in 1978 and from Wellesley College in 1974.

Dr. Newman served as the 2018-2019 President of the American Medical Women's Association (AMWA). During that time she led the development of a new AMWA Strategic Plan and created a committee to work on special challenges facing women with opioid addiction. She was appointed to the FDA Endocrinologic and Metabolic Drugs Advisory Committee (a committee of 11 members), for a four year term, beginning July 1, 2019. She is a Fellow of the American College of Physicians (ACP), the American Heart Association (AHA), and the American Medical Women's Association (AMWA).

Dr. Newman has expertise in lipids, diabetes, obesity and drug safety, and is recognized internationally for her work and publications on the safety of the statin class of medications. She was Chair of the Writing Committee for the 2019 American Heart Association Scientific Statement, "Statin Safety and Associated Adverse Events", published in the journal *ATVB*. The Statement assesses the causality of adverse events attributed to statins, and reviews statin safety in people with various diseases, and in children, the elderly, and pregnant women. She has expertise in large long-term randomized cardiovascular outcome trials, and served on the Steering Committee of the CARDS trial (of atorvastatin) in type 2 diabetes, and analyzed the efficacy and safety data from the SEARCH (simvastatin 20 mg vs 80 mg) and SHARP (ezetimibe + simvastatin) trials. She is a member of the Cholesterol Treatment Trialists' Collaboration that conducts meta-analyses of data from the statin outcome trials. She currently is Chair of the Writing Committee for the Endocrine Society Guideline, "Dyslipidemia in Endocrine Diseases" which is in preparation.

Her work in medical education has spanned 35 years, and currently addresses hypercholesterolemia and its management, cardiovascular risk, randomized controlled clinical trials, statin safety, and the pathophysiology and management of people with obesity. She was certified by the American Board of Obesity Medicine in 2018, is an attending physician consultant in a weight management clinic at the New York Harbor Veterans Affairs Medical Center in New York City. She is a member of the Endocrine Society (ES) Steering Committee that designs the program for the annual Clinical Endocrine Update, and previously chaired the Special Programs Committee which has responsibility for CME programs of the Endocrine Society. She serves on the Education Committee of the New York Chapter of the American College of Physicians. She has mentored numerous pre-medical and medical students, residents and fellows. She also lectures on burnout and resilience in physicians.

Dr. Newman continues to serve on the Board of Directors of Planned Parenthood of Northern, Central and Southern New Jersey, the Global Advisory Board of Planned Parenthood Federation of America (PPFA) and the PPFA Leadership Council. She previously served for six years on the PPFA National Medical Committee which sets the medical standards for PPFA health centers.

Dr. Newman is currently co-editing the first clinical textbook on how sex and gender impact clinical practice, for publication by Elsevier in 2020.